Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System

YUJI HEIKE, MAMI HOSOKAWA, SHOZO OSUMI, DAISUKE FUJII, KENJIRO AOGI, NAGIO TAKIGAWA, MIKIKO IDA, HISAO TAJIRI, KENJI EGUCHI, MIEKO SHIWA, RUMI WAKATABE, HISASHI ARIKUNI, YOICHI TAKAUE and SHIGEMITSU TAKASHIMA
Anticancer Research March 2005, 25 (2B) 1197-1203;
YUJI HEIKE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yheike@ncc.go.jp
MAMI HOSOKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOZO OSUMI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAISUKE FUJII
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJIRO AOGI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAGIO TAKIGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIKIKO IDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISAO TAJIRI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJI EGUCHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIEKO SHIWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RUMI WAKATABE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISASHI ARIKUNI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOICHI TAKAUE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGEMITSU TAKASHIMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 2B 1197-1203
PubMed 
15865066

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received August 9, 2004
  • Accepted January 27, 2005
  • Published online March 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. YUJI HEIKE1,2,3,
  2. MAMI HOSOKAWA1,2,
  3. SHOZO OSUMI1,
  4. DAISUKE FUJII1,
  5. KENJIRO AOGI1,
  6. NAGIO TAKIGAWA1,
  7. MIKIKO IDA1,
  8. HISAO TAJIRI1,
  9. KENJI EGUCHI1,
  10. MIEKO SHIWA4,
  11. RUMI WAKATABE4,
  12. HISASHI ARIKUNI5,
  13. YOICHI TAKAUE2 and
  14. SHIGEMITSU TAKASHIMA1
  1. 1Department of Medical Oncology and Clinical Research, National Shikoku Cancer Center, 13-Horinouchi, Matsuyama, Ehime 790-0007
  2. 2Hematopoietic Stem Cell Transplant/Immunotherapy Unit, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045
  3. 3Pharmacology Division, National Cancer Center Research Insitute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045
  4. 4Ciphergen Biosystems K.K., Yokohama Business Park Hi-tech Center 1F, 134 Godo-cho, Hodogaya-ku, Yokohama-shi, Kanagawa, 240-0005
  5. 5Sumitomo-Bioscience, Yokohama Business Park Hi-tech Center 1F, 134 Godo-cho, Hodogaya-ku, Yokohama-shi, Kanagawa, 240-0005, Japan
  1. Correspondence to: Yuji Heike, MD, PhD, Pharmacology Division, National Cancer Center Research Insitute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Tel: +81-3-3542-2511, Fax: +81-3-3547-5228, e-mail: yheike{at}ncc.go.jp

Cited By...

  • 34 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (2B)
Anticancer Research
Vol. 25, Issue 2B
1 Mar 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System
YUJI HEIKE, MAMI HOSOKAWA, SHOZO OSUMI, DAISUKE FUJII, KENJIRO AOGI, NAGIO TAKIGAWA, MIKIKO IDA, HISAO TAJIRI, KENJI EGUCHI, MIEKO SHIWA, RUMI WAKATABE, HISASHI ARIKUNI, YOICHI TAKAUE, SHIGEMITSU TAKASHIMA
Anticancer Research Mar 2005, 25 (2B) 1197-1203;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System
YUJI HEIKE, MAMI HOSOKAWA, SHOZO OSUMI, DAISUKE FUJII, KENJIRO AOGI, NAGIO TAKIGAWA, MIKIKO IDA, HISAO TAJIRI, KENJI EGUCHI, MIEKO SHIWA, RUMI WAKATABE, HISASHI ARIKUNI, YOICHI TAKAUE, SHIGEMITSU TAKASHIMA
Anticancer Research Mar 2005, 25 (2B) 1197-1203;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Proteomics of Breast Cancer: Principles and Potential Clinical Applications
  • MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients with Breast Cancer
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire